• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Philips CPAP recall could be an opportunity for ResMed, analysts say

Philips CPAP recall could be an opportunity for ResMed, analysts say

June 22, 2021 By Sean Whooley

ResMedBaird analysts say that the recall of certain sleep and respiratory devices by Royal Philips (NYSE:PHG) may benefit ResMed (NYSE:RMD).

Earlier this month, Amsterdam-based Philips provided an update on the April 26 recall for some bi-level PAP and CPAP ventilator devices with a foam component problem, with the company expecting revenue headwinds in its sleep and respiratory care business to be compensated by the performances of its other businesses. It elected not to change financial guidances provided with the initial recall announcement.

Analysts at Baird, however, noted that there is an opportunity for ResMed to get a jump on Philips amid the recall with its respiratory products, although there is a high degree of difficulty as far “meaningfully capitalizing on this disruption,” and few clear answers exist right now.

ResMed, one of the top-performing stocks of 2020, saw a 4.6% rise from market open to market close on June 14, the day Philips issued its update. The stock, which closed that day at $231.70 per share, has risen to as high as $242.50 per share in the week since then in the fallout of the recall.

The Baird report claimed that ResMed sales could grow by $100 million to $300 million, should approximately 10% to 20% of the affected Philips respiratory care machines move to ResMed. Analysts noted that one durable medical equipment provider that was historically a Philips shop, “placed a big ResMed order.”

Doctors told the analysts that the “degree of difficulty in meaningfully capitalizing on this disruption seems more like a three-point jump shot, potentially with a hand in face, than a layup.” A lot remains to be seen as far as ResMed’s ability to scale manufacturing to meet potential demand, should users of Philips devices look for alternatives.

Filed Under: Business/Financial News, Featured, Recalls, Respiratory, Wall Street Beat Tagged With: Philips, ResMed

More recent news

  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure
  • NanoVibronix enters into $50M financing agreement

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy